Etonogestrel Implant as Emergency Contraception

Launched by UNIVERSITY OF COLORADO, DENVER · Feb 1, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of an etonogestrel implant as a form of emergency contraception. The researchers want to find out if placing the implant before a certain hormonal change in the body, known as the LH surge, can prevent ovulation (the release of an egg). They believe that if the implant is inserted at the right time, it may stop ovulation from happening, which could help women avoid pregnancy without needing additional emergency contraception.

To join this study, participants should be women aged 18 to 40 with regular menstrual cycles and a BMI of 28 or less. They must not be pregnant or trying to get pregnant and should be willing to avoid certain medications during the study. If someone participates, they can expect to have the implant placed and then monitored through blood tests and ultrasounds to check hormone levels and ovulation. This research is important because it could provide new insights into how and when the implant can be used, making it easier for women to access effective contraception.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • BMI less than or equal to 28kg/m2
• • Intact uterus with at least one ovary
• • Regular menstrual cycles that occur every 21-35 days
• • If patient is postpartum or post-second trimester abortion, 3 menses (2 cycles) must have occurred prior to enrollment
• • If patient had a first trimester abortion or pregnancy loss, she must have one spontaneous menses prior to enrollment
• • Desires insertion of an etonogestrel contraceptive implant for contraception
• • Not currently pregnant or trying to become pregnant
• • Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study
• Exclusion Criteria:
• • Have a known hypersensitivity or contraindications to etonogestrel.
• • Medical conditions that affect liver function (e.g., hepatitis, cirrhosis; assessed via participant self-report)
• • Known or suspected current alcohol dependence syndrome or any illicit drug use that may affect the metabolism of the etonogestrel.
• • Uncontrolled thyroid disorder.
• • Use of long-acting injectable hormonal contraceptive within the past 9 months
• • Current use of hormonal oral, patch, intravaginal, or intrauterine contraception